3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Rituximab
63
Cyclophosphamide
57
fludarabine phosphate
40
fludarabine
37
ibrutinib
28
Lenalidomide
26
Bendamustine Hydrochloride
26
Filgrastim
20
venetoclax
19
obinutuzumab
17
Bortezomib
17
Peripheral Blood Stem Cell Transplantation
15
Etoposide
12
Biopsy
12
Tacrolimus
11
Specimen Handling
11
Melphalan
11
Interleukin-2
10
tanespimycin
9
Radiotherapy
9
Cytarabine
9
aldesleukin
8
Whole-Body Irradiation
8
Magnetic Resonance Spectroscopy
8
idelalisib
7
Vorinostat
7
Paclitaxel
7
Mycophenolic Acid
7
Ipilimumab
7
Cyclosporine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled